NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
P/B ratio for NRx Pharmaceuticals, Inc. (NRXP)
P/B ratio as of 2023: -2.97
According to NRx Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -2.97. At the end of 2022 the company had a P/B ratio of 98.53.
P/B ratio history for NRx Pharmaceuticals, Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -2.97 |
| 2022 | 98.53 |
| 2021 | 107.79 |
| 2020 | -191.04 |
| 2019 | 1.83 |
| 2018 | 1.31 |
| 2017 | 0.13 |